Pyxis Diagnostics – identifying predictive biomarkers for Cancer Immunotherapy
Cancer immunotherapy harness the immune system to eliminate cancer. Immune checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies have achieved remarkable success in some advanced cancer patients. However, there is still a significant proportion of patients that do not respond to treatments. Biomarkers are needed to screen for the benefit-seeking population, and to guide the development of new combination therapies.
Pyxis Diagnostics develops a unique platform to identify predictive biomarkers in the field of immuno-oncology. Biological data collected from fresh tumor samples (using cell-sorting, NGS and proteomics) enables deep characterization of the cancer cell, the different immune and the stromal cells. This profound analysis allows to delineate the Cellular Suppressive Network (CSN) formed within the tumor microenvironment. Machine learning algorithms are then can be used for classification of responders based on differential CSN patterns.
CTO – Dr. Reut Yosef